Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
18.54
-0.22 (-1.17%)
At close: Sep 4, 2025, 4:00 PM
18.50
-0.04 (-0.22%)
Pre-market: Sep 5, 2025, 4:20 AM EDT
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $8.47M in the quarter ending June 30, 2025, a decrease of -28.08%. This brings the company's revenue in the last twelve months to $60.27M, down -82.90% year-over-year. In the year 2024, Beam Therapeutics had annual revenue of $63.52M, down -83.18%.
Revenue (ttm)
$60.27M
Revenue Growth
-82.90%
P/S Ratio
27.32
Revenue / Employee
$124,787
Employees
483
Market Cap
1.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BEAM News
- 1 day ago - Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 10 days ago - Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - GlobeNewsWire
- 21 days ago - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 2 months ago - Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha
- 2 months ago - Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress - GlobeNewsWire
- 3 months ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - GlobeNewsWire
- 3 months ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire